Corient Capital Partners’s iShares Biotechnology ETF IBB Stock Holding History

Corient Capital Partners’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-1,589	Closed	-$207K	–	721
2022 Q1	$207K	Buy	1,589 +200	+14%	+$26.1K	0.01%	677
2021 Q4	$212K	Buy	+1,389	New	+$215K	0.01%	643
2017 Q3	–	Sell	-3,198	Closed	-$331K	–	291
2017 Q2	$331K	Hold	3,198	–	–	0.05%	244
2017 Q1	$313K	Hold	3,198	–	–	0.05%	247
2016 Q4	$283K	Sell	3,198 -300	-9%	-$27.3K	0.05%	261
2016 Q3	$338K	Buy	+3,498	New	+$333K	0.06%	240

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Corient Capital Partners's IBB Position: Q2 2022 in Review

Corient Capital Partners sold out of iShares Biotechnology ETF (IBB) in Q2 2022, closing a stake of 1,589 shares — an estimated $207K sold.

Corient Capital Partners first reported a position in IBB in Q3 2016 and held it in 6 quarters. The position peaked at $338K in Q3 2016. 858 funds tracked by Wall St. Rank hold IBB as of Q2 2022.

Corient Capital Partners reported no remaining iShares Biotechnology ETF position as of Q2 2022 after selling out during the quarter.
Corient Capital Partners sold 1,589 iShares Biotechnology ETF shares in Q2 2022, an estimated $207K.
Corient Capital Partners first reported a position in iShares Biotechnology ETF in Q3 2016 and held it in 6 quarters.
Corient Capital Partners's iShares Biotechnology ETF position peaked at $338K in Q3 2016.
858 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2022.

Based on Corient Capital Partners's 13F filing for Q2 2022, filed 12 Aug 2022.